Navigation Links
American Brain Tumor Association Supports $2 Million Glioblastoma Research Project
Date:9/3/2014

Chicago, IL (PRWEB) September 03, 2014

The American Brain Tumor Association (ABTA), in conjunction with the Brain Tumor Funder’s Collaborative (BTFC), is awarding a $2 million research grant to explore commonalities among long-term glioblastoma survivors around the world.

Glioblastoma is a common and aggressive type of brain tumor most prevalent in adults ages 45-65, and affects more men than women. This highly malignant tumor’s octopus-like tentacles make it difficult to remove completely during surgery, and with current treatments, median survival is about 14.6 months. A small percentage of patients experience better outcomes and become long-term survivors.

The Brain Tumor Funders’ Collaborative—a strategic partnership among advocacy organizations like the ABTA and private philanthropic groups—initiated a call for research proposals to investigate why only a minority of glioblastoma (GBM) patients achieves long-term survival.

The researchers aim to understand the basis for long-term survival with glioblastoma by comprehensively studying patient histories, tumor characteristics at the molecular genetic level, and effects of treatment. To do this, the researchers identified a large group of more than 300 patients who have survived glioblastoma for more than five years. Understanding the shared characteristics of long-term surviving patients allows for better understanding of the biology of this deadly disease, and will ultimately lead to improved treatments for all patients.

“We are proud to partner in this global initiative and support collaborative science which is vital to furthering our understanding of the characteristics of survivors and potentially uncover new research directions,” said Elizabeth M. Wilson, MNA, ABTA president and CEO. “Collaborations such as these support the ABTA’s mission to advance the understanding and treatment of brain tumors in an effort to improve, extend and ultimately save lives.”

The recipient of the BTFC grant is a research consortium led by the European Organization for Research and Treatment of Cancer (EORTC) and the Brain Tumor Center at the University Hospital in Zurich. The consortium, comprised of more than 20 Neuro-oncology Centers of Excellence across the globe, include researchers in Europe, the United States and Canada.

The project will be managed by Michael Weller, M.D., of the University Hospital Zurich and Patrick Yung Wen, M.D. of the Dana Farber Cancer Institute, in support of the EORTC.

About the American Brain Tumor Association
Founded in 1973, the American Brain Tumor Association was first and is now the only national organization committed to funding brain tumor research and providing information and education on all tumor types and all age groups. For more information, visit http://www.abta.org or call 800-886-ABTA (2282).

About the Brain Tumor Funders’ Collaborative
Inaugurated in 2003, the Brain Tumor Funders’ Collaborative (BTFC) is a strategic partnership among private philanthropic and advocacy organizations in the US and Canada to pool their resources and focus their research dollars toward advancing the understanding and treatment of brain tumors. The five members of the BTFC are: the American Brain Tumor Association, Brain Tumour Foundation of Canada, Children’s Brain Tumor Foundation, James S. McDonnell Foundation, and the Sontag Foundation.

About the European Organisation for Research and Treatment of Cancer
The European Organisation for Research and Treatment of Cancer (EORTC) is an International non-profit association (AISBL) founded in 1962 and established under the laws of Belgium. The aims of EORTC are to develop, conduct, coordinate, and stimulate translational and clinical research in Europe to improve the management of cancer and related problems by increasing survival but also patient quality of life. EORTC is both multinational and multidisciplinary, and the EORTC network comprises over 300 hospitals and cancer centers in over 30 countries, including about 2,500 collaborators from all disciplines involved in cancer treatment and research. The primary aim of the EORTC Brain Tumor Group (BTG) is to conduct, develop, coordinate, and stimulate clinical and translational research for the treatment of brain tumors and metastases.

# # #

Read the full story at http://www.prweb.com/releases/2014/09/prweb12139518.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. American Healthcare Documentation Professionals Group (AHDPG) Launches Free-Tuition Guarantee for Its ICD-10 Medical Coding Bridge Program
2. American Pain Society Returns with REMS Training at PAINWeek 2014 in Las Vegas
3. Pro Player Health Alliance Confirms Big Name Speakers at 2015 American Sleep and Breathing Academy Conference
4. Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans
5. Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing
6. Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5%
7. North American Seminars Master Clinicians Advanced Shoulder Course Receives PT Continuing Education Course Approval in Georgia, Pennsylvania, Massachusetts and Virginia
8. As Interest in Saunas Increases, the North American Sauna Society Increases Outreach to Provide Education on History, Design, and Culture
9. North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX
10. There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job
11. American Telemedicine Association Issues Clinical Guidelines for Telepathology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... , ... PKF O’Connor Davies , LLP, the nation’s 26th largest accounting ... Firm, will participate in the 40th Annual "Empire State Building Run Up" on Feb. ... steps, a vertical distance equal to about a fifth of a mile, to reach ...
(Date:1/23/2017)... ... ... plastic balance boards have been around since at least the 1950s and are a great ... and only balance board to use a patent-pending design featuring high-pressure inflation technology and drop-stitch ... well as skill-level adjustable for all ages and abilities. The board can be rolled ...
(Date:1/23/2017)... , ... January 23, 2017 , ... ... on Crystallization in Process Chemistry by Applying Simple PAT Tools . , ... compounds to isolate and purify the desired product. Chemists now spend more ...
(Date:1/23/2017)... ... January 23, 2017 , ... The ... of Anesthesiologists® (ASA®), the Foundation for Anesthesia Education and Research (FAER), the ... and the Cigna Foundation, encourages proposals supporting high quality research using perioperative ...
(Date:1/23/2017)... ... , ... “Life Under Blankets”: an entrancing story about one woman's travels ... is the creation of published author, Kimberly Mitchell, who earned her bachelor’s degree in ... to pursue a master’s degree in education in the field of curriculum and instruction. ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 2017 Endo International plc (NASDAQ / TSX: ... filed a joint motion in the U.S. District Court ... seeking the entry of a ten-year Stipulated Order ... between the FTC and Endo relating to the patent ... Opana® ER and Lidoderm® products.  It also resolves the ...
(Date:1/23/2017)... , Jan. 23, 2017 MouthWatch LLC announced today ... was ranked as the best intraoral camera on DentalCompare,s list ... #2 spot overall. The #1 product was the CollaPlug ... MouthWatch intraoral camera was "…incredibly popular because it is by ... has a small sticker price, it doesn,t sacrifice quality imaging." ...
(Date:1/23/2017)...  Allergan plc, (NYSE: AGN ), a leading ... International Headache Academy (IHA). Designed to inspire a long-term commitment ... offers a three-day, intensive overview on research and treatment options. ... sole sponsor since the inception of IHA in ... Europe in 2014. "Allergan ...
Breaking Medicine Technology: